SPOTLIGHT: Santhera inks licensing deal


Sweden's Biovitrum has acquired the rights to Santhera's DPP-IV inhibitor program to select and develop compounds and sell future drugs for a range of metabolic diseases, including type 2 diabetes, obesity and metabolic syndrome. Santhera gains €4 million up front with more than €50 million in back end potential. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.